CLINICAL TRIALS PROFILE FOR NEO-MEDROL ACETATE

All Clinical Trials for NEO-MEDROL ACETATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04515966 ↗	A Comparison of Ultrasound-guided Steroid Injection With Wrist Splint in Carpal Tunnel Syndrome	Recruiting	Mercy Health Ohio	Phase 4	2020-12-01	Carpal Tunnel Syndrome (CTS) is caused by compression of a nerve called the median nerve as it travels through a narrow tunnel within the wrist on its way to the hand. Compression of the median nerve causes numbness, tingling, pain and weakness of the hand and fingers. CTS is usually treated with rest or a change in the activity level. It can also be treated with a splint that limits bending of the hand and wrist. Other treatments include a steroid injection near the median nerve. Surgery can be performed if the symptoms are severe or persistent. Compression of the median nerve can cause swelling that may be observed with ultrasound of the wrist. Ultrasound can also be used to help guide the needle to inject the steroid solution in close proximity to the median nerve while avoiding injury to the nerve. The investigators plan to compare the effectiveness of a splint and an ultrasound-guided steroid injection in the treatment of mild to moderate CTS. Individuals with CTS who agree to participate, will be randomly assigned to two groups. One group will be treated with a splint and the other with a steroid injection performed under ultrasound guidance. The severity of CTS symptoms will be determined prior to beginning the study and also at 6 weeks, 3 months, 6 months and 1 year following each of the two treatment interventions. The median nerve size (diameter) will be measured in all participants prior to beginning the study and also following both treatment interventions at 6 weeks, 3 months, 6 months and 1 year. At the conclusion of the study, the investigators will determine which of the two treatments, splint or steroid injection, is more effective in alleviating CTS symptoms. The investigators will also determine if either or both treatments result in a change in swelling of the median nerve as measured by ultrasound.
NCT04757740 ↗	Comparison Between Platelet-rich Fibrin and Steroid for Intra-articular Injection for Sacroiliac Joint Dysfunction	Recruiting	Fayoum University Hospital	Phase 4	2021-03-01	Low back pain is one of the commonest complaints nowadays affecting nearly 20% of the population, Sacroiliac joint has been accused of being the primary cause of pain in about 10%: 27% of this population. The sure diagnosis of sacroiliac joint pain is challenging because of multiple crossed factors of facet joint pain and intervertebral disc pain. Diagnosis can be done by history taking, local examination, imaging techniques, and controlled local anesthetic blocks. Controlled local anesthetic blocks are diagnostic and therapeutic done by various methods either landmark-guided or imaging-assisted either by fluoroscopy, computed tomography (CT), magnetic resonance (MRI), or ultrasound-guided. Lower cost, real-time viewing of needle leading to higher accuracy rate, and low ionizing radiation dose are favoring ultrasound-guided injection over other modalities. Numerous treatment modalities are being used for sacroiliac joint pain ranging from physiotherapy and systemic analgesics like Non-steroidal anti-inflammatory drugs (NSAIDs) to minimally invasive intra-articular, periarticular injection, radiofrequency neurotomy, and surgical fusion of the joint. Multiple injectates are being used for intraarticular injection most commonly local anesthetics and steroids which offer short-term symptomatic relief and delay the degenerative process. The need for a longer duration effect directly affects the disease process itself aiming for accelerating the joint healing rate by biological growth factors found in human blood especially in platelets. Platelet-rich plasma (PRP) has been used aiming to inject a high concentration of growth factors directly into the joint. Platelet-rich fibrin (PRF), the second generation of platelet-rich plasma is now tried having the advantage of a simpler preparation and higher values of growth factors.

Clinical Trial Conditions for NEO-MEDROL ACETATE

Condition Name

Condition Name for NEO-MEDROL ACETATE
Intervention	Trials
Carpal Tunnel Syndrome	1
Low Back Pain	1

Condition MeSH

Condition MeSH for NEO-MEDROL ACETATE
Intervention	Trials
Syndrome	1
Carpal Tunnel Syndrome	1
Low Back Pain	1
Joint Diseases	1

Clinical Trial Locations for NEO-MEDROL ACETATE

Trials by Country

Trials by Country for NEO-MEDROL ACETATE
Location	Trials
United States	1
Egypt	1

Trials by US State

Trials by US State for NEO-MEDROL ACETATE
Location	Trials
Ohio	1

Clinical Trial Progress for NEO-MEDROL ACETATE

Clinical Trial Phase

Clinical Trial Phase for NEO-MEDROL ACETATE
Clinical Trial Phase	Trials
Phase 4	2

Clinical Trial Status

Clinical Trial Status for NEO-MEDROL ACETATE
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for NEO-MEDROL ACETATE

Sponsor Name

Sponsor Name for NEO-MEDROL ACETATE
Sponsor	Trials
Mercy Health Ohio	1
Fayoum University Hospital	1

Sponsor Type

Sponsor Type for NEO-MEDROL ACETATE
Sponsor	Trials
Other	2

NEO-MEDROL ACETATE Market Analysis and Financial Projection

Last updated: May 3, 2026

Clinical trials update, market analysis, and projection for NEO-MEDROL ACETATE

What is NEO-MEDROL ACETATE and what is known about its clinical development?

NEO-MEDROL ACETATE is a brand name tied to methylprednisolone acetate, a corticosteroid suspension used for anti-inflammatory and immunosuppressive indications. No complete, reliable, drug-specific clinical trial register footprint (phase-by-phase trial listings, active status, study identifiers) could be established from available public sources in this session. The analysis below therefore treats the product as a market-facing corticosteroid acetate whose clinical evidence is primarily anchored in the long-established methylprednisolone acetate class rather than in a uniquely identifiable, brand-driven late-stage clinical program.

Implication for “clinical trials update”: a credible, date-stamped update requires trial identifiers tied to the exact named product; that data is not available here in a complete form.

What is the therapeutic market for methylprednisolone acetate (and where does NEO-MEDROL ACETATE fit)?

Methylprednisolone acetate sits in the broader systemic corticosteroids and injectable anti-inflammatory market. These products compete on:

• Formulation and dosing (strength per mL, suspension characteristics)
• Injection site and administration (IM/ intra-articular use patterns depending on local labeling)
• Cost and procurement channel access (tender-driven in many markets)
• Manufacturing continuity (shortages drive substitution to equivalents)

In most geographies, corticosteroid injection demand is driven by chronic disease management (rheumatology), acute inflammatory flares (orthopedics), and specialty care patterns (pain management and musculoskeletal injections).

---

Market analysis: demand, pricing drivers, and competitive structure

How does demand typically form for corticosteroid injectables?

Demand for methylprednisolone acetate injectable products typically concentrates in:

• Rheumatology and musculoskeletal services (intra-articular and IM use patterns depending on labeling and payer protocols)
• Acute inflammatory conditions treated in ambulatory and outpatient settings
• Procedure-adjacent care where corticosteroid injections are used as standard-of-care adjuncts

The market is less characterized by innovation-driven adoption and more by access, formulary inclusion, and supply reliability.

What pricing and reimbursement forces matter most?

For older corticosteroid injectables, pricing power usually comes from:

• Tender outcomes and hospital contracting
• Switching costs (if a formulary already standardizes on a specific steroid suspension)
• Availability and distribution
• Pack format and strength (unit economics for single administration)

Where multiple equivalents exist, the market tilts toward lower net price unless differentiation is introduced through supply assurance or product presentation.

Who competes with NEO-MEDROL ACETATE?

Competition typically includes:

• Other methylprednisolone acetate injectable brands
• Alternatives across the corticosteroid injection class (e.g., triamcinolone acetonide, betamethasone formulations, depending on local labeling)
• Generic substitutes when available

Because NEO-MEDROL ACETATE maps to a well-established active ingredient, brand differentiation generally does not extend beyond manufacturing and supply chain parameters.

---

Projections: what to expect for sales and growth

What drives near-term growth or decline for methylprednisolone acetate injections?

Short-cycle drivers include:

• Hospital and clinic substitution cycles tied to tender calendars
• Supply disruptions shifting share among equivalents
• Clinician preference stability for a given injection suspension characteristics

Long-cycle drivers include:

• Population aging and musculoskeletal disease prevalence
• Healthcare utilization trends and reimbursement behavior

What market trajectory is most plausible for an older corticosteroid injectable?

For mature steroid injectables, realistic growth usually comes from:

• Unit growth (patient volume, clinic utilization)
• Share shifts between equivalent products through contracting
• Price movement limited by generics and tender pressure

A conservative base-case projection for NEO-MEDROL ACETATE should assume low single-digit value growth driven by volume and procurement dynamics rather than technology-driven expansion.

No numeric projections are provided because there is no accessible, brand-specific dataset in this session to anchor:

• historic sales,
• local market share,
• product-level pricing,
• tender wins/losses,
• mapped indications by country,
• or registered clinical activity tied to the named product.

---

Actionable business view

Where can NEO-MEDROL ACETATE win fastest?

1. Formulary and tender placements where clinicians already use corticosteroid injections and substitution is price- and availability-driven.
2. Supply reliability as the differentiator when equivalent products experience stock volatility.
3. Account-based execution in rheumatology, orthopedics, pain management, and outpatient injection clinics.

What are the key diligence items for forecasting?

Even without numeric projections here, the forecast should be stress-tested against:

• tender schedule exposure,
• generic entry and equivalent brand substitution intensity,
• distribution channel concentration (hospital group vs wholesalers),
• and any label or presentation changes that alter contracting eligibility.

---

Key Takeaways

• NEO-MEDROL ACETATE is positioned as methylprednisolone acetate injectable corticosteroid; clinical development updates cannot be product-uniquely verified here via complete trial registers.
• The market is mature and procurement-driven, where growth depends on tender access, contracting, volume, and supply continuity rather than pipeline breakthroughs.
• A realistic projection for an older corticosteroid injectable should assume limited value growth and share dynamics as the main swing factor; no brand-level numeric forecast is produced because the needed product-specific inputs are not present in this session.

---

FAQs

1) Is NEO-MEDROL ACETATE a new molecular entity?
No indication of novelty is present in this session; it corresponds to methylprednisolone acetate, an established corticosteroid active.

2) Are there identifiable late-stage clinical trials unique to the NEO-MEDROL ACETATE brand in this update?
No complete, brand-specific phase-by-phase trial register footprint is available here.

3) What matters most for commercialization of older corticosteroid injectables?
Tender outcomes, formulary inclusion, net pricing, and consistent supply.

4) What is the likely competitive set?
Other methylprednisolone acetate equivalents and alternative corticosteroid injections, varying by local labeling and procurement rules.

5) How should market projections be structured?
Use a procurement-and-share model anchored to contracting calendars, expected substitution pressure, and volume utilization trends rather than innovation adoption curves.

---

References (APA)

[1] FDA. (n.d.). Drugs@FDA: FDA-approved Drug Products. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. (n.d.). European public assessment reports (EPARs) and medicines. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] ClinicalTrials.gov. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/